Non-selective β-adrenergic blocker with vasodilating activity. Prepn: BE 868943 (1979 to Bristol-Myers); W. E. Kreighbaum, W. T. Comer, US 4234595 (1980 to Mead Johnson); W. E. Kreighbaum et al., J. Med. Chem. 23, 285 (1980). Crystal structure: J.-M. Léger et al., Acta Crystallogr. C40, 706 (1984). Conformation: E. Coutinho, Indian J. Chem. 34B, 553 (1995). Review of chemistry and pharmacology: D. Deitchman et al., in New Drugs Annual: Cardiovascular Drugs vol. 1, A. Scriabine, Ed. (Raven Press, New York, 1983) pp 1-18. Clinical pharmacokinetics: P. A. Meredith et al, Xenobiotica 15, 979 (1985). Clinical pharmacology: N. Bett et al., Am. J. Cardiol. 57, 678 (1986). GC-MS determn in plasma: M. J. Bartek et al., J. Chromatogr. 377, 183 (1986). Evaluation in congestive heart failure: M. R. Bristow et al., Circulation 89, 1632 (1994).
Antihypertensive; in treatment of congestive heart failure.
β-Adrenergic Blocker; Antihypertensive; Aryloxypropanolamine Derivatives